drugset / Trial / NCT00066417
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
Open-labelTreatment
Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2007-01
Outcome
Outcome not reported
Stopped: “Trial was withdrawn for drug availability issues.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Cyclosporine | Peptide | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |
| Background | Thiotepa | Other / unclassified | — | Intravenous |
| Background | therapeutic allogeneic lymphocytes | Cell therapy | — | — |